Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Phumla Sinxadi
Observed names:
P Sinxadi,
Phumla Z Sinxadi,
Phumla Z. Sinxadi,
Phumla Zuleika Sinxadi,
Sinxadi, Phumla
Institutions:
South African Medical Research Council,
University of Cape Town,
Groote Schuur Hospital
Observed institutions:
South African Medical Research Council,
Meharry Medical College,
University of Cape Town,
Vanderbilt University,
Groote Schuur Hospital,
Wellcome Centre for Infectious Diseases Research in Africa,
Institute of Infectious Disease and Molecular Medicine
show all 7
ORCID:
0000-0002-1312-3523
Observed ORCID:
0000-0002-1312-3523
OpenAlex ID:
A5085277129
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
2020
·
Rulan Griesel
, Gary Maartens
, et al.
·
Clinical Infectious Diseases
·
95
PDF
Pharmacogenetics of plasma efavirenz exposure in HIV‐infected adults and children in South Africa
2015
·
Phumla Z. Sinxadi
, Paul D. Leger
, et al.
·
British Journal of Clinical Pharmacology
·
84
PDF
Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
2020
·
Phumla Sinxadi
, Cristina Donini
, et al.
·
Antimicrobial Agents and Chemotherapy
·
64
Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing Regimens
2020
·
Michael A Leonard
, Zinhle Cindi
, et al.
·
Clinical Infectious Diseases
·
60
Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype
2013
·
Helen M. McIlleron
, Michael Schomaker
, et al.
·
AIDS
·
54
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens
2024
·
Simiso Sokhela
, Willem D F Venter
, et al.
·
Open Forum Infectious Diseases
·
50
PDF
Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations
2016
·
Phumla Zuleika Sinxadi
, Helen Margaret McIlleron
, et al.
·
Medicine
·
42
A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women
2019
·
Tamsin K. Phillips
, Phumla Sinxadi
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
39
PDF
The long wait for long-acting HIV prevention and treatment formulations
2024
·
Willem Daniel Francois Venter
, Monica Gandhi
, et al.
·
The Lancet HIV
·
28
Warfarin resistance.
2008
·
P Sinxadi
, M Blockman
·
PubMed
·
23
Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus
2022
·
Zinhle Cindi
, Aida N Kawuma
, et al.
·
The Journal of Infectious Diseases
·
22
Therapeutic drug monitoring of antiretrovirals for people with HIV
2008
·
Tamara Kredo
, Jan-Stefan Van der Walt
, et al.
·
Cochrane Database of Systematic Reviews
·
22
Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy
2021
·
Rulan Griesel
, Aida N. Kawuma
, et al.
·
British Journal of Clinical Pharmacology
·
20
PDF
Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites
2018
·
Eric H Decloedt
, Phumla Z Sinxadi
, et al.
·
Journal of Antimicrobial Chemotherapy
·
20
PDF
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study
2024
·
Sam Nightingale
, Anna J Dreyer
, et al.
·
The Lancet HIV
·
19
Understanding the Implications of Mitochondrial DNA Variation in the Health of Black Southern African Populations: The 2014 Workshop
2015
·
Francois H. van der Westhuizen
, Phumla Z. Sinxadi
, et al.
·
Human Mutation
·
19
PDF
Mitochondrial Genomics and Antiretroviral Therapy-Associated Metabolic Complications in HIV-Infected Black South Africans: A Pilot Study
2013
·
Phumla Z. Sinxadi
, Joel A. Dave
, et al.
·
AIDS Research and Human Retroviruses
·
19
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial
2019
·
Willem D F Venter
, Michelle Moorhouse
, et al.
·
The Lancet HIV
·
17
Weight gain on dolutegravir: Association is not the same as causation
2023
·
Gary Maartens
, Phumla Sinxadi
, et al.
·
Southern African Journal of HIV Medicine
·
16
Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS)
2021
·
Roland van Rensburg
, Sam Nightingale
, et al.
·
Clinical Infectious Diseases
·
16
Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
2023
·
Aida N. Kawuma
, Roeland E. Wasmann
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
13
PDF
Building Capability for Clinical Pharmacology Research in Sub‐Saharan Africa
2017
·
MM Gutierrez
, G Pillai
, et al.
·
Clinical Pharmacology & Therapeutics
·
13
Pharmacogenomics of Hypertension in Africa: Paving the Way for a Pharmacogenetic‐Based Approach for the Treatment of Hypertension in Africans
2023
·
Jonathan N. Katsukunya
, Nyarai D. Soko
, et al.
·
International Journal of Hypertension
·
12
PDF
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens
2021
·
Zinhle Cindi
, Gary Maartens
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
12
Obesity is South Africa’s new HIV epidemic
2024
·
Nomathemba Chandiwana
, Willem Venter
, et al.
·
South African Medical Journal
·
11
PDF
Show more works
View as search
Works count:
74
Citation count:
937
H-index:
17
I10-index:
30
Year
Topic
Type
